

Dixon's research has focused on a group of proteins that govern a chemical reaction called "phosphorylation," the addition or removal of phosphate molecules from proteins. This biochemical reaction serves as a major signaling mechanism in cells, including growth factors, neuronal firing, or even the presence of an invading pathogen. Dixon's work has gained insights into the plague, Down Syndrome and cancer, lack Dixon is also on the external advisory board of the U-M Life Sciences Institute

Schlessinger studies the mechanism of activation of receptor tyrosine kinases (RTKs) and how RTKs are maintained in an inactive state prior to growth factor stimulation. Growth factor stimulation activates recruitment and control of cellular signaling pathways. He is also interested in new approaches for the discovery of drugs to treat diseases caused by aberrant activation of RTKs or dysfunction in their signaling pathways, including cancer.



Jack E. Dixon, PhD
Dean of Scientific Affairs
Professor of Pharmacology.
Cellular & Molecular Medicine, and
Chemistry & Biochemistry
University of California – San Diego



Joseph Schlessinger, PhD William H. Prusoff Professor & Chairman of Pharmacology Yale University School of Medicine

8:45 am
Welcome
Alan Saltiel
Director of the
Life Sciences Institute


9:00 am
The Intersection Between
Bacterial Pathogens and
Eukaryotic Signal Transduction Systems

9:50 am

Cell Signaling by Tyrosine

Phosphorylation: From

the Bench to the Bedside



Doudna's research concerns the structure and function of RNA molecules, including ribozymes and viral RNAs. She is comparing catalytic strategies used by RNA to those of protein enzymes, focusing on self-splicing introns and the self-cleaving RNA from hepatitis delta virus (HDV), a human pathogen. Doudna is also investigating RNA-mediated initiation of protein synthesis in hepatitis C virus, and RNA-protein complexes involved in targeting proteins for export out of cells. Professor Doudna is also on the external advisory board of the U-M Life Sciences Institute



Peter Agre, MD
2003 Nobel Laureate
in Chemistry
Professor of Biological Chemistry
& Medicine
Jennifer A. Doudna, PhD
Investigator
Howard Hughes Medical Institute
Professor, Molecular & Cell Biology
University of California—Berkeley

1:00 pm

Of Motions and Metals:

Diverse Catalytic Strategies of Natural

11:00 am
Mary Sue and Kenneth
Coleman Life Sciences
Lecture:
Aquaporin Water
Channels — From Atomic
Structures to Clinical
Medicine
Introduction by
President Mary Sue Coleman

aporin Water Ribozymes nnels — From Atomic uctures to Clinical dicine

Noon – 1:00 pm Break

School of Medicine

Horwich studies a cellular machine called chaperonin that assists proteins in folding to their native, functional, form inside the cell. This machine uses the energy of ATP in alternating and repeating cycles of conformational change. Related work investigates a chaperone system that uses ATP to unfold proteins. His group also has been analyzing the structure of an amyloid, a protein aggregate that builds up in a variety of neurodegenerative diseases, including Alzheimer's.

Hopkins has identified mutations in roughly 25% of the genes essential for the development of a 5-dayold zehrafish larva. Almost every one of these genes has a homologue in humans and 20% of them encode proteins whose biochemical function is unknown. Her work has identified pathways of develcoment and disease for kidney. cartilage, jaw, liver, and hearing, Collaborations with 25 external labs are helping to identify the genes involved in formation of many other embryonic vertebrate organs and cell types. Hopkins and her collaborators have also found a novel class of tumor suppressors in the collection

Schekman is interested in protein trafficking between intracellular membranes and the cell surface, using yeast as a model organism. His genetic and biochemical approach to the study of eukaryotic membrane traffic has shown that protein transport in yeast appears to be mediated by the same organelles and proteins that operate in mammalian cells. Professor Schekman is also on the external advisory board of the U-M Life Sciences Institute.



Arthur L. Horwich, MD Investigator Howard Hughes Medical Institute Professor of Genetics & Pediatrics Yale University School of Medicine



Nancy Hopkins, PhD Amgen, Inc. Professor of Biology Massachusetts Institute of Technology



Randy Schekman, PhD Investigator Howard Hughes Medical Institute Professor of Molecular & Cell Biology University of California – Berkeley

1:50 pm The Chaperonin Folding Machine 3:00 pm The Genes Essential for Early Zebrafish Development 3:50 pm Mechanism and Regulation of Vesicle Biogenesis in the Secretory Pathway The Life Sciences Institute at the University of Michigan is the core of a campus-wide effort to expand teaching and learning in the life sciences. A multidisciplinary team of LSI scientists collaborate and share ideas in an open lab setting. The 230,000 square foot institute building opened in September 2003.

LSI researchers are exploring the complexity of life at the level of molecules and cells using the tools of genetics, genomics and proteomics, structural, chemical and computational biology, molecular and cellular biology and chemical genomics.

The annual LSI symposium highlights recent scientific developments and provides an opportunity for Michigan's students and scientists to interact with and learn from prominent scientific leaders.

Isi.umich.edu



Isiamichiedu

The Regents of the University of Michigan:

David A. Brandon, Ann Arbor; Laurence B. Deitch, Bingham Farms; Olivia P. Maynard, Goodrich; Rebecca McGowan, Ann Arbor; Andrea Fischer Newman, Ann Arbor; Andrew C. Richner, Grosse Pointe Park; S. Martin Taylor, Grosse Pointe Farms; Katherine E. White, Ann Arbor; Mary Sue Coleman (ex officio)

The University of Michigan, as an equal opportunity/ affirmative action employer, complies with all applicable federal and state laws regarding nondiscrimination and affirmative action, including Title IX of the Education Amendments of 1972 and Section 504 of the Rehabilitation Act of 1973. The University of Michigan is committed to a policy of nondiscrimination and equal opportunity for all persons regardless of race, sex, color, religion, creed, national origin or ancestry, age, marital status, sexual orientation, disability, or Vietnam-cra veteran status in employment, educational programs and activities, and admissions. Inquiries or complaints may be addressed to the Senior Director of Institutional Equity and Title IX/Section 504 Coordinator, Office of Institutional Equity, 2072 Administrative Services Building, Ann Arbor, Michigan 48109-1432, 734-763-0235, TTY 734-647-1388. For other University of Michigan Information call 734-764-1817.